

1
2 **Longitudinal SARS-CoV-2 testing is punctuated by intermittent positivity and variable**
3 **rates of cycle-threshold decline**
4

5 Shawn E. Hawken¹, Subhashini A. Sellers², Jason R. Smedberg¹, Jeremy D. Ward³, Herbert C.
6 Whinna³, William Fischer², Melissa B. Miller^{1,3*}

7
8 1. Clinical Microbiology Laboratory, McLendon Clinical Laboratories, UNC Medical Center,
9 Chapel Hill, NC.

10 2. Department of Medicine, Division of Pulmonary Diseases and Critical Care Medicine; School
11 of Medicine; University of North Carolina at Chapel Hill

12 3. Department of Pathology and Laboratory Medicine; School of Medicine; University of North
13 Carolina at Chapel Hill

14

15 *Corresponding author:

16 Melissa B. Miller, PhD

17 101 Manning Drive, East Wing 1035

18 Chapel Hill, NC 27514

19 Melissa.Miller@unhealth.unc.edu

20

21

22 **Abstract**

23 The COVID-19 pandemic is complicated by cases of vaccine-breakthrough, re-infection, and
24 widespread transmission of variants of concern (VOC). Consequently, the need to interpret
25 longitudinal positive SARS-CoV-2 (SCV-2) tests is crucial in guiding clinical decisions
26 regarding infection control precautions and treatment. Although quantitative tests are not
27 routinely used diagnostically, standard diagnostic RT-PCR tests yield Ct values that are inversely
28 correlated with RNA quantity. In this study, we performed a retrospective review of 72,217
29 SCV-2 PCR positive tests and identified 264 patients with longitudinal positivity prior to
30 vaccination and VOC circulation. Patients with longitudinal positivity fell into two categories:
31 short-term (207, 78%) or prolonged (57, 22%) positivity, defined as ≤ 28 (range 1-28, median
32 16) days and >28 (range 29- 152, median 41) days, respectively. In general, Ct values declined
33 over time in both groups; however, 11 short-term positive patients had greater amounts of RNA
34 detected at their terminal test compared to the first positive, and 5 patients had RNA detected at
35 $Ct < 35$ at least 40 days after initial infection. Oscillating positive and negative results occurred
36 in both groups, although oscillation was seen three times more frequently in prolonged-positive
37 patients. Patients with prolonged positivity had diverse clinical characteristics but were often
38 critically ill and were discharged to high-level care or deceased (22%). Overall, this study
39 demonstrates that caution must be emphasized when interpreting Ct values as a proxy for
40 infectivity, predictor of severity, or a guide for patient care decisions in the absence of additional
41 clinical context.

42

43

44 **Background**

45 The global burden of morbidity and mortality caused by SARS-CoV-2 (SCV-2) is
46 concentrated among vulnerable patients with comorbidities (1). While most patients test negative
47 after 14 days, cases where patients remain RNA positive months later have been observed (2–5).
48 The recent emergence of vaccine-breakthrough cases, re-infections, and widespread transmission
49 of variants of concern (VOC), such as World Health Organization lineage Delta, which appears
50 to rise to higher viral titers, underscore the clinical imperative to interpret positive SCV-2 results
51 from the same patient over time. Unfortunately, current gold-standard RT-PCR clinical
52 diagnostic tests are not quantitative (6, 7). While RT-PCRs yield Ct values that are inversely
53 correlated with the amount of RNA present in a sample, they are influenced by patient,
54 specimen, and diagnostic test characteristics (8, 9).

55 The debate over if and how to use Ct values clinically is underscored by recent
56 statements from professional societies including the joint statement from the Infectious Diseases
57 Society of America (IDSA) and the Association for Molecular Pathology (AMP) and a statement
58 from the College of American Pathologist (CAP), in response to growing interest in using Ct
59 values as surrogate measure of a patients viral load (8, 9). Proponents of using Ct values to guide
60 clinical decisions infer Ct values as a snapshot of viral burden in a patient’s sample, and there is
61 interest in clinical evaluation of Ct trends to discern the clinical and epidemiological relevance of
62 a positive test (9, 10). Unfortunately, the observation that a subset of patients will test positive,
63 typically with a higher Ct value several months after initial infection are a challenge clinically,
64 since it is often unclear if these patients are still infectious and what distinguishes these patients
65 from the majority of SCV-2 patients who instead convert to a negative test weeks after infection
66 (3–5). Here we sought to describe the natural history of SCV-2 test results, including Ct values,

67 among patients who tested positive multiple times at our institution in a time period prior to
68 vaccine roll-out and VOC circulation. We describe the duration of positivity and clinical
69 characteristics of the population of patients with prolonged SCV-2 positivity. This investigation
70 serves to highlight challenges in using Ct values to guide clinical decisions.

71

72 **Methods**

73 Study design and participants

74 We performed a descriptive retrospective review of all patients who underwent testing for SCV-
75 2 RNA at the University of North Carolina Medical Center Clinical Microbiology Laboratory
76 between March 17, 2020 and October 15, 2020. This study was approved by the Institutional
77 Review Board at the University of North Carolina at Chapel Hill (IRB# 20-2448).

78

79 SARS-CoV-2 RNA testing

80 During the study timeframe, four platforms were used by our laboratory for the detection
81 of SCV-2 RNA. Three of these assays, the Abbott Alinity m SARS-CoV-2 assay, Abbott
82 RealTime SARS-CoV-2 assay (Abbott Molecular Inc, Green Oaks, IL), and Cepheid Xpert®
83 Xpress SARS-CoV-2 (Cepheid, Sunnyvale, CA) had accessible cycle threshold data that was
84 exported from the instruments. Ct values were not available from an Emergency use
85 authorization (EUA) laboratory developed test that was used on a minority of specimens. To
86 adjust for cycle threshold reporting differences between instruments, 10 cycles were added to Ct
87 values from the Abbott M2000 assay to account for the 10 hidden cycles in the analysis software
88 (Abbott Molecular Inc, personal communication).

89

90 Clinical chart review and data abstraction

91 Basic demographic information and SCV-2 test results (positive and negative tests,
92 specimen type, testing platform, Ct values) were abstracted from electronic medical records
93 (EMR) and the laboratory information system for all patients tested for SCV-2 RNA during the
94 study period. We queried these reports to identify patients with multiple positive tests and
95 examined the timing of positive tests to identify patients who had evidence of long-term
96 positivity of SCV-2 RNA. Patients who demonstrated positivity later than the 3rd quartile of all
97 patients with multiple positive tests were considered “long-term” positive patients and were
98 investigated further by chart review. Manual chart review of the EMR was performed to abstract
99 patient age, gender, body mass index (BMI), hospital admission dates, and discharge disposition.
100 Medication exposure for long-term positive patients was collected via EMR reports.

101 SCV-2 testing data were evaluated in relation to positive and negative testing dates to
102 describe the characteristics of the patient population with prolonged positivity and to summarize
103 patterns of clinical exposures surrounding dates where patients either tested negative or positive
104 for SCV-2.

105

106 Statistical analysis

107 All descriptive statistics and data analysis were performed using R version 3.6.1 (11).

108

109 **Results**

110 Summary of SARS-CoV2 testing during study

111 Between March 16 and October 15, 2020 our hospital performed 72,217 RT-PCR tests
112 for SCV-2 including 4,609 positive and 67,608 negative tests across six different specimen types

113 including 67,612 (93%) nasopharyngeal swabs. RT-PCR tests were performed across four
114 platforms: 18,057 EUA LDT, 7,014 Cepheid Xpert, 23,983 Abbott Alinity m, and 23,163 Abbott
115 RealTime (m2000). Among the 58,348 patients tested, 9,682 (16.6%) were tested multiple times
116 and 264 (0.45%) patients had at more than one positive test (**Supplemental Figure 1**). Among
117 264 patients with multiple positive tests, the median interval between first and last positive test
118 was 16 days (range 1-152) with 118 (44.7%) of patients first and last testing positive within a
119 single 14-day incubation period. We took advantage of a natural breakpoint in the distribution of
120 duration of positivity to define prolonged positivity as $>3^{\text{rd}}$ quartile (28 days) duration between
121 first and last positive tests (**Figure 1**). Prolonged SCV-2 positivity was observed in 57 patients
122 who remained positive for 29-152 (median 41) days.

123

124 *Diagnostic testing characteristics of patients with multiple SCV-2 positive tests*

125 Among the 207 patients with multiple positive tests who did not have prolonged
126 positivity, 17 (8.2%) had patterns of intermittent positivity with at least one negative test (range
127 0-3 negative tests) between their first and last positive test. This pattern was observed over three-
128 times more frequently among the 57 prolonged positive patients among whom 16 (28%) had
129 intermittent positivity ($p < 0.001$).

130 While Ct values generally declined over time, variable rates of decline in Ct values were
131 observed in individual patients (**Figure 2 A-B, Supplemental Figure 2**). Among patients
132 without prolonged positivity, 123 (59%) had Ct values available from both the first and last
133 (terminal) positive test. Among these patients, terminal positive tests were median 9.8 cycles
134 higher compared to first positive tests, signaling lower amounts of RNA detected; however, 11
135 patients had higher amounts of RNA detected at their last positive test compared to first positive

136 test which occurred between 3 and 25 days later. Overall, terminal positive tests ranged from
137 22.5 cycles lower to 31.8 cycles higher, with terminal positives testing near the limit of detection
138 (>35) for 21 (17%) patients. For prolonged positive patients' terminal and initial test Ct data was
139 available for 36 patients (63%). Terminal positive tests were a median of 14 (range 2-26) cycles
140 greater than initial positive tests.

141 In contrast to patients without prolonged positivity, no prolonged positive patients had
142 terminal test Ct values that were lower than their initial positive test (i.e., increase in amount of
143 RNA detected). Consistent with continued viral RNA decline over time, 33 (91%) prolonged
144 positive patients had terminal positive tests near the limit of detection (>35 Ct); however, by day
145 40 post initial positive test, 5 (13.8%) patients still had Ct values <35 and one patient tested
146 positive with a Ct value <35 109 days after initial positive (**Figure 3**).

147

148 Demographic and treatment characteristics of prolonged positive patients

149 Patients with prolonged positivity are a population where the examination of Ct values is
150 an attractive method to help guide clinical decisions. Clinical characteristics of the 57 prolonged
151 positive patients included: obesity 30%, hospitalization 53%, discharge to long-term care 35%,
152 hospice or deceased 23%. In general, prolonged positive patients experienced a severe course of
153 illness, with 33% treated with immune modulating drugs and 10% treated with remdesivir
154 (**Table 1**).

155

156 Discussion

157 Here we describe the natural history of SCV-2 RNA testing among all patients who tested
158 positive multiple times at our institution during a seven-month period, revealing complex

159 patterns of intermittent positivity and variable decline of viral RNA detected via Ct values
160 throughout different stages of infection. Although factors observed among prolonged positive
161 patients were similar to those described in patients with severe COVID disease, 47% of
162 prolonged positive patients were not ill enough to require hospitalization, underscoring that a
163 large subset of healthier patients may experience prolonged RNA positivity (1, 12). Intriguingly,
164 11 patients without prolonged positivity demonstrated greater amounts of RNA detected at their
165 terminal versus initial SCV-2 positive test, suggesting variable shedding even early in their
166 infection (2). Additional factors such as timing of initial presentation and specimen quality,
167 likely contribute to RNA detection or observed decline (2, 5, 13, 14). Although it was beyond the
168 scope of this study to evaluate likelihood of re-infection, which would require longitudinal viral
169 sequencing, the observation of decreased RNA detection over time in the majority of patients
170 was consistent with a single infection course, since re-infection is currently thought to be rare,
171 especially prior to widespread VOC circulation (18).

172 The observation of intermittent positivity in 8% of patients with multiple SCV-2 positive
173 tests during a time period prior to sustained VOC transmission suggests sample quality may play
174 a major role in Ct results (13). Interestingly, prolonged positive patients were over three times
175 more likely to have intermittent positivity. These intermittent negatives may be explained by
176 variable shedding dynamics, therapeutic interventions, sample quality, among other variables,
177 which will need to be investigated in future studies in order to better understand this
178 phenomenon and how it pertains to infectivity and the clinical course of these patients.

179 As the pandemic progresses in time, and VOC capable of high-titer and vaccine
180 breakthrough infections such as Delta gain in prevalence, longitudinal testing information with
181 variability in Ct values will become available for a greater number of patients. With the added

182 complexity of novel variant circulation, it will become even more crucial to keep the possibility
183 of variable shedding in mind at any stage of infection and exercise caution when interpreting Ct
184 values as proxy measures for infectivity and severity. Development and deployment of
185 diagnostic tests that can discriminate between prolonged shedding and reinfection and provide
186 insight into infectiousness is urgently needed for the next stage of the SCV-2 pandemic.

187

188 **Acknowledgments**

189 We would like to thank the staff of the Clinical Microbiology and Molecular Microbiology
190 Laboratories at UNC Medical Center for their tireless efforts during the pandemic and their role
191 in performing the clinical SCV-2 tests described in this study.

192

193 **References**

- 194 1. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M, Wu B, Yang Z, Zhang C, Yue J,
195 Zhang Z, Renz H, Liu X, Xie J, Xie M, Zhao J. 2020. Risk factors for severity and
196 mortality in adult COVID-19 inpatients in Wuhan. *Journal of Allergy and Clinical
197 Immunology* 146:110–118.
- 198 2. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. 2021. SARS-CoV-2, SARS-
199 CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a
200 systematic review and meta-analysis. *The Lancet Microbe* 2:e13–e22.
- 201 3. Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, Barbian K,
202 Judson SD, Fischer ER, Martens C, Bowden TA, Wit E de, Riedo FX, Munster VJ. 2020.

- 203 Case Study: Prolonged infectious SARS-CoV-2 shedding from an asymptomatic
204 immunocompromised cancer patient. *Cell* 0.
- 205 4. Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman M, Wobus CE,
206 Adams M, Washer L, Martin ET, Luring AS. Prolonged SARS-CoV-2 replication in an
207 immunocompromised patient. *J Infect Dis* <https://doi.org/10.1093/infdis/jiaa666>.
- 208 5. Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W, Li Y, Ni Q, Zou R, Li X, Xu M, Zhang Y,
209 Zhao H, Zhang X, Yu L, Su J, Lang G, Liu J, Wu X, Guo Y, Tao J, Shi D, Yu L, Cao Q,
210 Ruan B, Liu L, Wang Z, Xu Y, Liu Y, Sheng J, Li L. 2020. Factors Associated With
211 Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19).
212 *Clinical Infectious Diseases* 71:799–806.
- 213 6. Fang FC, Benson CA, del Rio C, Edwards KM, Fowler VG, Fredricks DN, Limaye AP,
214 Murray BE, Naggie S, Pappas PG, Patel R, Paterson DL, Pegues DA, Petri WA, Schooley
215 RT. 2020. COVID-19—Lessons Learned and Questions Remaining. *Clin Infect Dis*
216 *ciaa1654*.
- 217 7. Rhoads DD, Cherian SS, Roman K, Stempak LM, Schmotzer CL, Sadri N. 2020.
218 Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA Emergency Use
219 Authorization Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal
220 Swabs from Individuals Diagnosed with COVID-19. *J Clin Microbiol* 58:e00760-20.
- 221 8. IDSA and AMP joint statement on the use of SARS-CoV-2 PCR cycle threshold (Ct) values
222 for clinical decision-making. [https://www.idsociety.org/globalassets/idsa/public-](https://www.idsociety.org/globalassets/idsa/public-health/covid-19/idsa-amp-statement.pdf)
223 [health/covid-19/idsa-amp-statement.pdf](https://www.idsociety.org/globalassets/idsa/public-health/covid-19/idsa-amp-statement.pdf) [Accessed September 28, 2021].

- 224 9. Rhoads D, Peaper DR, She RC, Nolte FS, Wojewoda CM, Anderson NW, Pritt BS. 2021.
225 College of American Pathologists (CAP) Microbiology Committee Perspective: Caution
226 Must Be Used in Interpreting the Cycle Threshold (Ct) Value. *Clinical Infectious Diseases*
227 72:e685–e686.
- 228 10. Important Issues to Consider Before Interpreting and Applying Ct Values in Clinical
229 Practice. Association for Molecular Pathology. [https://www.amp.org/about/news-](https://www.amp.org/about/news-room/amp-blog-content/important-issues-to-consider-before-interpreting-and-applying-ct-values-in-clinical-practice/)
230 [room/amp-blog-content/important-issues-to-consider-before-interpreting-and-applying-ct-](https://www.amp.org/about/news-room/amp-blog-content/important-issues-to-consider-before-interpreting-and-applying-ct-values-in-clinical-practice/)
231 [values-in-clinical-practice/](https://www.amp.org/about/news-room/amp-blog-content/important-issues-to-consider-before-interpreting-and-applying-ct-values-in-clinical-practice/) [Accessed September 28, 2021].
- 232 11. R CT. 2019. R: A language and environment for statistical computing. R Foundation for
233 Statistical Computing, Vienna, Austria.
- 234 12. Flerlage T, Boyd DF, Meliopoulos V, Thomas PG, Schultz-Cherry S. 2021. Influenza virus
235 and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. *Nat Rev*
236 *Microbiol* 19:425–441.
- 237 13. Richard-Greenblatt M, Ziegler MJ, Bromberg V, Huang E, Abdallah H, Tolomeo P,
238 Lautenbach E, Glaser L, Kelly BJ. 2021. Quantifying the Impact of Nasopharyngeal
239 Specimen Quality on Severe Acute Respiratory Syndrome Coronavirus 2 Test Performance.
240 *Open Forum Infectious Diseases* 8.
- 241 14. Rao SN, Manissero D, Steele VR, Pareja J. 2020. A Narrative Systematic Review of the
242 Clinical Utility of Cycle Threshold Values in the Context of COVID-19. *Infect Dis Ther*
243 9:573–586.


244 15. Walensky RP, Walke HT, Fauci AS. 2021. SARS-CoV-2 Variants of Concern in the United
245 States—Challenges and Opportunities. JAMA 325:1037.

246

247


248


249 Figure Legends




250

251 Figure 1. Summary of time between first and last positive test for patients with multiple
252 positive tests. Y-axis indicates days between first and last positive test, individual dots indicate
253 individual patients. Blue indicates prolonged positive patient defined at natural breakpoint of >
254 3rd quartile duration, grey indicates short-term positive patient. Violin and box plot indicate
255 overall distribution of days between first and last positive test.





257
258 Figure 2. Distribution of Ct values over time for patients with and without prolonged positivity.
259 X-axis indicates days between positive tests, y-axis indicates cycle-threshold of clinical tests. A.
260 patients without prolonged positivity. B. patients with prolonged positivity. Symbols indicate
261 nasopharyngeal swab or other specimen type. Violin and box plot indicate distribution of Ct
262 values at timeframe specified on x-axis.



263

264 Figure 3. SCV-2 testing summary for patients with slow Ct value decline defined as Ct values <35

265 after 40 days post initial positive test. X-axis indicates time, y axis indicates 1 patient per grey

266 line. Red and blue dots indicate positive and negative SCV-2 tests respectively. Table 1. Clinical

267 characteristics of patients with prolonged SCV-2 positivity.

268


269 Table 1. Clinical characteristics of patients with prolonged SCV-2 positivity.

	Overall (N=57)
Sex	
F	31 (54 %)
M	26 (46 %)
BMI (kg/m²)	
Mean (SD)	31 (± 9.8)
Missing	25 (43.9%)
Age (years)	
Mean (SD)	49 (± 20)
Missing	1 (1.8%)
Cycle threshold first positive	
Mean (SD)	23 (± 6.0)
Missing	13 (22.8%)
Cycle threshold last positive	
Mean (SD)	37 (± 3.2)
Missing	11 (19.3%)
Time between first and last positive (days)	
Mean (SD)	51 (± 27)
Admitted	
admitted	30 (53 %)
never admitted	27 (47 %)
Discharge_disposition	
Assisted Living	2 (4 %)
Deceased	1 (2 %)
Home	17 (30 %)
Hospice	1 (2 %)
Never Admitted	27 (47 %)
Rehab	1 (2 %)
SNF	6 (11 %)
Missing	2 (3.5%)


270

271

272 **Supplemental Information**



273
274 Figure S1. Timeline of SCV-2 testing throughout study for patients with at least 2 positive SCV-
275 2 tests. X-axis indicates time, y axis indicates 1 patient per grey line. Red and blue dots indicate
276 positive and negative SCV-2 tests respectively.



277

278 Figure S2. Timeline of Ct values for prolonged positive patients with intermittent positive and
279 negative tests. Y axis indicates Ct value, X axis indicates days from first positive test. Patients
280 are represented by number in grey box at top of each plot. Red line indicates negative test. Tests
281 are only plotted if negative or positive and a Ct value was available.

282

283

284

285